固形腫瘍治療薬の市場規模、シェア、成長分析、治療タイプ別、がん適応症別、エンドユーザー別、地域別 - 2025年～2032年の産業予測

固形腫瘍治療薬の世界市場規模は2023年に1,770億6,000万米ドルとなり、2024年の1,915億8,000万米ドルから2032年には3,598億9,000万米ドルに成長し、予測期間（2025年～2032年）のCAGRは8.20％で成長する見通しです。

世界の固形腫瘍治療薬市場は、乳がん、肺がん、大腸がん、前立腺がん等のがん症例の増加により拡大しており、高齢化やがんリスク因子を増加させるライフスタイルの変化がその要因となっています。効果的な治療法への需要が、従来の化学療法に代わる標的療法や免疫療法などの先進的な治療法の採用を促しています。新療法に対する規制当局の承認が相次ぎ、がん治療薬のパイプラインが充実していることが、市場の成長をさらに促しています。バイオマーカーやゲノム・プロファイリングによる個別化医療のための研究開発投資の増加も注目に値します。ヘルスケア支出の増加、新興国でのアクセス改善、バリュー・ベース・ケアの重視といった要因が、革新的な固形がん治療薬の採用を世界的に促進しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 顧客購買行動分析

固形腫瘍治療薬の市場規模：治療タイプ別& CAGR（2025年～2032年）

• 市場概要
• 化学療法
• 標的療法
• 免疫療法
• ホルモン療法
• その他

固形腫瘍治療薬の市場規模：がん適応症別& CAGR（2025年～2032年）

• 市場概要
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• 肝臓がん
• その他

固形腫瘍治療薬の市場規模：エンドユーザー別& CAGR（2025年～2032年）

• 市場概要
• 病院
• がん研究センター
• 専門クリニック

固形腫瘍治療薬の市場規模& CAGR（2025年～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022年～2024年）

主要企業プロファイル

• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• AstraZeneca plc（United Kingdom）
• Bristol Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Sanofi S.A.（France）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Gritstone Bio, Inc.（USA）
• Black Diamond Therapeutics, Inc.（USA）

結論と提言

Global Solid Tumor Therapeutics Market size was valued at USD 177.06 Billion in 2023 and is poised to grow from USD 191.58 Billion in 2024 to USD 359.89 Billion by 2032, growing at a CAGR of 8.20% in the forecast period (2025-2032).

The global solid tumor therapeutics market is expanding due to a rise in cancer cases like breast, lung, colorectal, and prostate cancers, fueled by aging populations and lifestyle changes that increase cancer risk factors. The demand for effective therapies is prompting the adoption of advanced treatment options, including targeted therapies and immunotherapies, as alternatives to traditional chemotherapy. An influx of regulatory approvals for new therapies and a robust oncology drug pipeline are further stimulating market growth. Increased investment in R&D for personalized medicine, driven by biomarkers and genomic profiling, is also noteworthy. Contributing factors such as rising healthcare spending, improved access in emerging economies, and the focus on value-based care are facilitating greater adoption of innovative solid tumor therapies worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Solid Tumor Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Solid Tumor Therapeutics Market Segments Analysis

The global solid tumour therapeutics market is segmented based on therapy type, cancer indication, end user, and region. In terms of therapy type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. Based on cancer indication, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, and others. Based on end user, the market is segmented into hospitals, cancer research centers, and specialty clinics. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Solid Tumor Therapeutics Market

One of the key market drivers for the global solid tumor therapeutics market is the increasing prevalence of solid tumors due to rising risk factors such as aging populations, unhealthy lifestyle choices, and environmental influences. As the incidence of various solid tumors, including breast, lung, and colorectal cancers, continues to escalate, there is a growing demand for effective therapeutic options. Additionally, advancements in cancer research and technology have facilitated the development of targeted therapies and immunotherapies, providing more effective treatment modalities. This convergence of rising patient needs and innovative treatment approaches is significantly propelling market growth.

Restraints in the Global Solid Tumor Therapeutics Market

One significant market restraint for the global solid tumor therapeutics market is the high cost associated with the development and commercialization of innovative treatments. The complex nature of solid tumors often necessitates extensive research and clinical trials, which can lead to substantial financial investments. This economic burden can limit access for patients, particularly in developing regions, and may deter both pharmaceutical companies and investors from pursuing new therapies. Additionally, stringent regulatory requirements can further complicate the approval process, causing delays and increasing overall development costs, thereby hindering the growth potential of the market.

Market Trends of the Global Solid Tumor Therapeutics Market

The global solid tumor therapeutics market is witnessing a significant trend towards the integration of AI and digital pathology for enhanced treatment personalization. These technological advancements are revolutionizing tumor characterization, enabling oncologists to develop tailored treatment plans that are more effective and efficient. By leveraging AI-powered diagnostics, healthcare providers can improve patient outcomes through greater predictability of results. This shift is driving the broader adoption of precision medicine, allowing for targeted therapies that cater to the unique genetic profiles of various cancers. As a result, the market is becoming increasingly focused on innovative, data-driven approaches to solid tumor treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Solid Tumor Therapeutics Market Size by Therapy Types & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Others

Global Solid Tumor Therapeutics Market Size by Cancer Indication & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Others

Global Solid Tumor Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Cancer Research Centers
• Specialty Clinics

Global Solid Tumor Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Types, Cancer Indication, End User)
  • US
  • Canada
• Europe (Therapy Types, Cancer Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Types, Cancer Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Types, Cancer Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Types, Cancer Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Black Diamond Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations